India · Delayed Price · Currency is INR Venus Remedies Statistics
Total Valuation
Venus Remedies has a market cap or net worth of INR 23.89 billion. The enterprise value is 22.98 billion.
| Market Cap | 23.89B |
| Enterprise Value | 22.98B |
Important Dates
The last earnings date was Monday, July 20, 2026.
| Earnings Date | Jul 20, 2026 |
| Ex-Dividend Date | Aug 7, 2026 |
Share Statistics
| Current Share Class | 13.37M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.20% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 29.52% |
| Owned by Institutions (%) | 1.16% |
| Float | 6.41M |
Valuation Ratios
The trailing PE ratio is 20.57.
| PE Ratio | 20.57 |
| Forward PE | n/a |
| PS Ratio | 2.94 |
| PB Ratio | 3.60 |
| P/TBV Ratio | 4.19 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 19.79 |
| EV / Sales | 2.83 |
| EV / EBITDA | 13.76 |
| EV / EBIT | 16.44 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.07 |
| Debt / FCF | n/a |
| Interest Coverage | 4,661.00 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 18.71% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | 5.59% |
| Revenue Per Employee | 6.25M |
| Profits Per Employee | 894,838 |
| Employee Count | 1,298 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Venus Remedies has paid 354.30 million in taxes.
| Income Tax | 354.30M |
| Effective Tax Rate | 23.37% |
Stock Price Statistics
The stock price has increased by +211.48% in the last 52 weeks. The beta is 0.25, so Venus Remedies's price volatility has been lower than the market average.
| Beta (5Y) | 0.25 |
| 52-Week Price Change | +211.48% |
| 50-Day Moving Average | 1,550.63 |
| 200-Day Moving Average | 938.36 |
| Relative Strength Index (RSI) | 48.49 |
| Average Volume (20 Days) | 60,774 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Venus Remedies had revenue of INR 8.11 billion and earned 1.16 billion in profits. Earnings per share was 86.89.
| Revenue | 8.11B |
| Gross Profit | 4.14B |
| Operating Income | 1.40B |
| Pretax Income | 1.52B |
| Net Income | 1.16B |
| EBITDA | 1.67B |
| EBIT | 1.40B |
| Earnings Per Share (EPS) | 86.89 |
Balance Sheet
The company has 1.03 billion in cash and 124.10 million in debt, with a net cash position of 910.00 million.
| Cash & Cash Equivalents | 1.03B |
| Total Debt | 124.10M |
| Net Cash | 910.00M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 6.64B |
| Book Value Per Share | 496.59 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 271.88M |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 51.02%, with operating and profit margins of 17.24% and 14.32%.
| Gross Margin | 51.02% |
| Operating Margin | 17.24% |
| Pretax Margin | 18.68% |
| Profit Margin | 14.32% |
| EBITDA Margin | 20.59% |
| EBIT Margin | 17.24% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 10.00, which amounts to a dividend yield of 0.56%.
| Dividend Per Share | 10.00 |
| Dividend Yield | 0.56% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.20% |
| Shareholder Yield | 0.77% |
| Earnings Yield | 4.86% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |